Browse the evidence

Intensive glycemic control (target HbA1c < 6%) significantly reduces the development of diabetic peripheral neuropathy (DPN) in patients with Type 1 Diabetes Mellitus (T1DM), but this benefit is not observed in patients with Type 2 Diabetes Mellitus (T2DM).

If you have Type 1 Diabetes, aiming for an HbA1c below 6% is the most effective way to prevent nerve damage. However, if you have Type 2 Diabetes, this aggressive target is not recommended due to lack of neuropathy benefit and increased mortality risk; standard control (7.0-7.9%) is advised instead.

Semaglutide significantly improves glycemic control (HbA1c and fasting blood glucose) and systolic blood pressure in overweight or obese adults, with or without type 2 diabetes.

Semaglutide not only helps with weight loss but also significantly improves blood sugar control (HbA1c and fasting glucose) and lowers systolic blood pressure in overweight or obese individuals, offering potential cardiovascular benefits.

Achieving and maintaining diabetes remission (HbA1c <48 mmol/mol off glucose-lowering medications) is associated with a significantly lower incidence of Major Adverse Diabetic Events (MADE) compared to those not in remission.

Achieving diabetes remission is not just about feeling better; it actively protects your kidneys, eyes, and nerves from long-term damage. By maintaining remission through weight loss and lifestyle changes, you significantly lower your risk of serious diabetic complications.

A ketogenic diet significantly reduces HbA1c levels in overweight T2DM patients, though it does not significantly affect fasting glucose, fasting insulin, or HOMA-IR compared to control diets.

While a ketogenic diet effectively lowers long-term average blood sugar (HbA1c) in T2DM patients, it may not immediately change fasting blood glucose or insulin resistance scores (HOMA-IR) compared to other diets. This suggests the benefit is in sustained glucose regulation rather than acute fasting metrics.

Genetic variants in GLP1R (rs6923761) and TCF7L2 (rs7903146) influence the response to liraglutide, with specific genotypes associated with greater reductions in body fat and weight.

If you are taking liraglutide, your genetic makeup might influence how much fat or weight you lose. Some genetic variants are linked to better outcomes with this drug. This is not a reason to start or stop treatment, but may help explain individual differences in response.

Time-restricted feeding (TRF) improves insulin sensitivity and glycemic control (including reduced glucose variability and HbA1c) in individuals with overweight or obesity, independent of significant weight loss in some studies.

If you have insulin resistance or pre-diabetes, try shifting your eating window to end earlier in the evening (e.g., 8 PM) and start later in the morning (e.g., 4 PM). This timing aligns with your body's natural circadian rhythms, helping to lower blood sugar spikes and improve how your body uses insulin, even if the scale doesn't move dramatically.

Alternate-Day Fasting (ADF) improves insulin sensitivity (HOMA-IR) more than Continuous Energy Restriction (CER).

If you are using Alternate-Day Fasting, you may see improvements in insulin sensitivity that are not seen with standard calorie restriction. This is a potential metabolic benefit of ADF.

Semaglutide and Liraglutide reduce the risk of Major Adverse Cardiovascular Events (MACEs), whereas Naltrexone/Bupropion increases the risk of elevated blood pressure.

If you have obesity and cardiovascular risks, Semaglutide or Liraglutide are preferred because they reduce MACE risk. Avoid Naltrexone/Bupropion if you have hypertension, as it increases blood pressure risk.

Time-restricted eating (TRE) significantly reduces diastolic blood pressure (DBP) in adults with obesity, but does not significantly affect systolic blood pressure (SBP).

If you have high blood pressure, TRE might help lower your diastolic (bottom) number, but don't expect it to significantly change your systolic (top) number. This is a secondary benefit to weight loss, not a primary treatment for hypertension.

Intermittent Fasting improves metabolic health markers, including insulin sensitivity, lipid profiles (reduced triglycerides and LDL), and blood pressure, independent of weight loss magnitude, through mechanisms involving ketone body production and hormonal regulation.

Beyond weight loss, IER can improve your blood lipids and blood pressure. This happens partly because your body switches to burning fat for fuel (ketones) during fasting periods, which improves insulin sensitivity and reduces inflammation. You do not need to lose a massive amount of weight to see these metabolic benefits.

Sulfur amino acid restriction (SAAR) significantly decreases serum leptin levels and increases plasma ketone bodies (beta-hydroxybutyrate and acetoacetate) compared to a control diet, indicating a shift in metabolic fuel usage.

Reducing sulfur amino acids lowers leptin (a hormone that signals fat stores to the brain) and increases ketones. This suggests your body is switching to burning fat for fuel more efficiently, which may help sustain weight loss.

VLCD intervention significantly increases Sex-Hormone-Binding Globulin (SHBG) and reduces fasting blood glucose in obese women with PCOS, whereas moderate energy deficit does not significantly alter these specific metabolic markers over 8 weeks.

VLCDs offer a metabolic advantage over moderate dieting for PCOS patients by significantly boosting SHBG and lowering fasting glucose. This suggests VLCD may be necessary to reverse the underlying insulin resistance driving hyperandrogenism in some patients.

Fasting-based strategies improve insulin sensitivity (reduced fasting insulin and HOMA-IR) in the short term compared to continuous caloric restriction, but this benefit is not sustained in long-term outcomes for fasting glucose.

If you are obese, trying fasting strategies (like time-restricted eating) may help improve your insulin sensitivity in the first few months compared to just counting calories. This is measured by lower fasting insulin levels. However, this doesn't necessarily mean you will lose more weight in the long run, so use this metabolic benefit as one factor in choosing your strategy.

Intermittent fasting significantly improves lipid profiles by reducing total cholesterol and LDL, but may temporarily increase triglycerides in short-term interventions (≤ 12 weeks).

Intermittent fasting improves total cholesterol and LDL, key markers for heart health. However, be aware that triglycerides may temporarily rise in the first 12 weeks as your body adapts. This is often a transient phase. If you have high baseline triglycerides, consult a healthcare provider and consider longer-term adherence to see the full lipid benefits.

Intermittent fasting significantly reduces diastolic blood pressure but has no significant effect on systolic blood pressure, fasting plasma glucose, or HbA1c in overweight and obese adults.

Intermittent fasting can help lower diastolic blood pressure, a key component of heart health. However, it may not significantly affect systolic blood pressure or blood sugar levels (FPG, HbA1c) in the short term. For comprehensive cardiometabolic health, combine IF with other lifestyle interventions and monitor your specific markers.

A ketogenic diet significantly improves quality of life (QoL) and reduces fatigue symptoms in individuals with overweight, particularly those with high baseline fatigue.

If you are overweight and struggle with fatigue, a ketogenic diet may help boost your energy and overall quality of life. This benefit seems most pronounced if you already feel fatigued. Stick to the diet for at least three months, ensure you are in ketosis, and monitor how your energy levels change.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) achieve 10-15% weight loss and superior metabolic improvements compared to lifestyle changes alone, but are recommended for non-responders or those with comorbidities.

If lifestyle changes alone do not achieve sufficient weight loss or if you have obesity-related comorbidities, discuss GLP-1 receptor agonists (like semaglutide or liraglutide) with your doctor. These medications can lead to 10-15% weight loss and significant metabolic improvements, though they may cause gastrointestinal side effects. They are most effective when combined with lifestyle modifications.

Tirzepatide produces significant weight loss (mean 18.73%) and improves quality of life in overweight or obese adults without diabetes, but significantly increases the risk of adverse events compared to placebo.

Tirzepatide is a highly effective treatment for weight loss in non-diabetic overweight or obese adults, producing an average 18.73% body weight loss. However, it comes with a significantly higher risk of adverse events, particularly gastrointestinal issues, compared to placebo. Patients should be monitored closely for these side effects.

Intermittent fasting downregulates enteroendocrine signaling, specifically GLP-1, GCG, and PYY, while upregulating PPAR-α, which correlates with improved lipid profiles.

The molecular changes observed (PPAR-α upregulation, GLP-1 downregulation) suggest that IF works by altering how your body processes fats and regulates hormones, not just by restricting calories. This may inform future targeted therapies.

Increasing the regularity of meal times (reducing mealtime variability) leads to significant weight loss without the need for calorie restriction or changes in macronutrient composition.

Use a smartphone app to track your meals for two weeks. Identify the specific times you eat most frequently. Then, for the next six weeks, restrict your eating to only those specific times, aiming for a consistency of within 45 minutes of your usual times. Do not worry about changing what or how much you eat. This regularity helps your body's internal clock optimize metabolism, leading to weight loss.

Semaglutide improves glycemic control and metabolic parameters in patients with Type 2 Diabetes and obesity.

For those with Type 2 Diabetes, semaglutide helps manage blood sugar and aids in weight loss, though the weight loss effect may be more modest compared to non-diabetic patients.

Dietary fiber fermentation by gut microbiota produces short-chain fatty acids (SCFAs) which stimulate the secretion of gut peptides (GLP-1, PYY) via GPR41/GPR43 receptors, thereby improving glucose regulation and reducing energy intake.

To leverage your gut microbiome for better blood sugar control and appetite regulation, consume complex carbohydrates (dietary fibers) that resist digestion in the small intestine. These fibers reach the colon where bacteria ferment them into short-chain fatty acids (SCFAs). These SCFAs activate specific receptors (GPR41/43) on gut cells, triggering the release of hormones like GLP-1 and PYY that improve glucose handling and reduce hunger. Focus on sources like resistant starches and arabinoxylans.

Exogenous advanced glycation end products (AGEs) from heat-processed foods contribute significantly to systemic AGE accumulation, promoting oxidative stress, inflammation, and insulin resistance in type 2 diabetes.

Limit high-heat cooking methods like grilling, frying, and baking. Opt for moist-heat cooking (steaming, boiling, poaching) to reduce dietary AGE intake, which may help lower systemic inflammation and improve insulin sensitivity in type 2 diabetes.

SSB consumption increases the risk of type 2 diabetes (T2DM) and cardiovascular disease (CVD) independently of, and mediated by, weight gain.

Even if you are not overweight, limiting SSBs is important for preventing type 2 diabetes and heart disease. The sugars in these drinks can negatively affect your metabolism, insulin response, and blood lipids independently of your weight.